Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "BAL-Pharma"

536 News Found

Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets
Drug Approval | March 24, 2023

Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets

Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).


OPPI launches ‘Bharat Ke Liye’ to reinforce commitment to improve health outcomes
Healthcare | March 23, 2023

OPPI launches ‘Bharat Ke Liye’ to reinforce commitment to improve health outcomes

This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India


Lupin receives approval from USFDA for Brexpiprazole Tablets
Drug Approval | March 22, 2023

Lupin receives approval from USFDA for Brexpiprazole Tablets

Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)


Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets
Drug Approval | March 21, 2023

Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets

According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million


Caplin receives USFDA approval for Rocuronium Bromide Injection
Drug Approval | March 21, 2023

Caplin receives USFDA approval for Rocuronium Bromide Injection

Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)


Lupin Digital Health reveals results of digital therapeutics study with ACS patients
Digitisation | March 18, 2023

Lupin Digital Health reveals results of digital therapeutics study with ACS patients

The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform


Briefs: Lupin and Alembic
News | March 14, 2023

Briefs: Lupin and Alembic

Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.


Agilent announces digital pathology workflow solution
Digitisation | March 13, 2023

Agilent announces digital pathology workflow solution

Open, scalable, end-to-end solution to improve diagnostic quality and efficiency


USFDA completes inspection of Lupin’s Vizag facility
Drug Approval | March 11, 2023

USFDA completes inspection of Lupin’s Vizag facility

The inspection concluded with no observations


Aptar appoints Julie Xing to its Board of Directors
People | March 07, 2023

Aptar appoints Julie Xing to its Board of Directors

Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.